- Home
- RBOT vs ALXO Comparison
RBOT vs ALXO Comparison
Compare RBOT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- ALXO
- Stock Information
- Founded
- RBOT 2014
- ALXO 2015
- Country
- RBOT United States
- ALXO United States
- Employees
- RBOT N/A
- ALXO N/A
- Industry
- RBOT Medical Specialities
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- ALXO Health Care
- Exchange
- RBOT Nasdaq
- ALXO Nasdaq
- Market Cap
- RBOT 61.4M
- ALXO 58.9M
- IPO Year
- RBOT N/A
- ALXO 2020
- Fundamental
- Price
- RBOT $6.18
- ALXO $1.17
- Analyst Decision
- RBOT Hold
- ALXO Strong Buy
- Analyst Count
- RBOT 1
- ALXO 6
- Target Price
- RBOT $7.00
- ALXO $3.30
- AVG Volume (30 Days)
- RBOT 36.5K
- ALXO 1.7M
- Earning Date
- RBOT 08-12-2025
- ALXO 08-12-2025
- Dividend Yield
- RBOT N/A
- ALXO N/A
- EPS Growth
- RBOT N/A
- ALXO N/A
- EPS
- RBOT N/A
- ALXO N/A
- Revenue
- RBOT N/A
- ALXO N/A
- Revenue This Year
- RBOT N/A
- ALXO N/A
- Revenue Next Year
- RBOT N/A
- ALXO N/A
- P/E Ratio
- RBOT N/A
- ALXO N/A
- Revenue Growth
- RBOT N/A
- ALXO N/A
- 52 Week Low
- RBOT $5.00
- ALXO $0.40
- 52 Week High
- RBOT $19.00
- ALXO $2.42
- Technical
- Relative Strength Index (RSI)
- RBOT 36.78
- ALXO 69.75
- Support Level
- RBOT $5.89
- ALXO $1.05
- Resistance Level
- RBOT $6.91
- ALXO $1.22
- Average True Range (ATR)
- RBOT 0.74
- ALXO 0.13
- MACD
- RBOT -0.10
- ALXO 0.03
- Stochastic Oscillator
- RBOT 6.29
- ALXO 87.67
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.